Olaparib Improves Outcomes in BRCA-Altered Castration-Resistant Prostate Cancer

Mutations in the DNA damage repair genes BRCA 1 and BRCA2 increase a tumor’s susceptibility to treatment with poly(ADP)ribose polymerase (PARP) inhibitors. This treatment approach is standard in breast and ovarian cancers, where these mutations commonly occur. Mutations in BRCA1/2 and the DNA damage repair gene ATM occur in as many as 30% of patients […]

Read More

CDK4/6 Inhibitors Demonstrate Consistent Survival Benefit in Breast Cancer

For patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, treatment with a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor in combination with endocrine therapy is a highly effective treatment option. Three CDK4/6 inhibitors are currently approved in the United States in this setting. At the ESMO Congress 2019, final results from the MONARCH 2 […]

Read More

Postsurgical Radiotherapy Not Necessary for Prostate Cancer

For men with early-stage prostate cancer, the standard of care for many years has been radical prostatectomy followed by adjuvant radiotherapy to prevent disease recurrence. However, the benefits of radiotherapy in this setting are not well documented and can be associated with numerous toxic effects. At the ESMO Congress 2019, results from a large clinical […]

Read More

Nivolumab/Ipilimumab Associated With High Rates of Long-Term Survival in Melanoma

In the past decade, the 5-year survival rate for patients with metastatic melanoma has increased dramatically, from less than 5% with chemotherapy to 20% with ipilimumab monotherapy. More recently, the introduction of PD-1 and PD-L1 inhibitors into the care of patients with metastatic melanoma has further improved survival outcomes, particularly when used in combination with […]

Read More

Two Years of Hormone Therapy Increases Mortality in Recurrent Prostate Cancer

Treatment with antiandrogen therapy is a standard of care for men with prostate cancer receiving salvage radiotherapy following postsurgical biochemical recurrence. This standard, based in part on results from the randomized phase III RTOG 9601 trial, found that the addition of 2 years of antiandrogen therapy to postoperative radiotherapy resulted in a significant improvement in […]

Read More

Survival Benefit for Induction Chemo in Nasopharyngeal Carcinoma

The majority of patients diagnosed with nasopharyngeal carcinoma are at an advanced stage and have a poor prognosis. Concurrent platinum-based chemotherapy and radiation is currently the standard of care for these patients with high risk, but this treatment is associated with a high rate of relapse. In phase II trials, induction chemotherapy with gemcitabine and […]

Read More